Xaira's X-Design model designs functional antibodies against an "undruggable" target
DaveJuergens · x · 2026-10-03
AI drug discovery company Xaira Therapeutics unveiled X-Design, its molecular AI design model, and published a blog post showing de novo antibody design results.
- The goal is to tackle the hardest, most clinically relevant targets traditional methods can't solve, combining top-tier research, engineering and wet-lab capabilities in a model focused on clinically progressible molecules.
- First showcase: de novo design of functional, progressible antibodies for its "undruggable" XA-4 program.
- Xaira argues AI antibody design needs to prove at least one of two things: yielding a fully progressable binder (human, potent, selective, developable) faster/cheaper than traditional methods on real targets, or succeeding where traditional and prior computational approaches have failed — with recalcitrant GPCRs as a key example.
Related event: Xaira Unveils X-Design, De Novo Antibody Design Model(2 posts)→
More from Companies & People
- Founder Regrets Not Taking His Company Public While Watching Anthropic's IPO — SatelliteNetSec · 2026-11-20
- Wired podcast: the outages, Anthropic's IPO money, and AI chips post-Jensen Huang — Wired AI · 2026-11-20
- Nous Research partners with Microsoft to bring Hermes Agent into Teams and Azure — NousResearch · 2026-11-20
- Brad Gerstner says Jensen Huang case may involve no legal violation, warns Nvidia board still must explain — garrytan · 2026-11-20
- Taco Bell's voice AI hits 900+ drive-thrus, lifts sales 1.5% and satisfaction 6% — Scobleizer · 2026-11-20
- GDM Insider Pushes Back on Talent-Drain Narrative: Alphabet's AI Bench Is 'Almost Comical' — zacharynado · 2026-11-20